Trial Profile
Adjuvant vs. progression-triggered treatment with gemcitabine after radical cystectomy for locally advanced transitional cell carcinoma of the bladder in patients not suitable for cisplatin-based chemotherapy - a phase 3 study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.
- 16 Feb 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
- 16 Feb 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.